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Abstract A characteristic of sporadic and familial breast
tumours is genomic instability, resulting from either
inherited mutations in genes that control genome integrity
or mutations that are acquired in somatic cells during
development. It is well established that abnormal chro-
mosome number and structural changes to chromosomes
play an important role in the cause and progression of
breast cancer. Familial BRCA1 breast tumours are charac-
terised by basal-like phenotype and high-histological grade
which are typically associated with increased genomic
instability. Consistent with previous studies, the genomes
with the greatest number of base pairs covered by copy
number change were typically found in basal-like and/or
high-histological grade breast tumours within our cohort.
Moreover, we show that luminal A tumours that are high
grade had significantly less copy number variant (CNV)
coverage than the more clinically aggressive high-grade
luminal B tumours, suggesting that chromosomal instabil-
ity rather than cellular differentiation contributes to the
aggressive nature of luminal B tumours. It has previously
been proposed that germline CNVs may contribute to
somatically acquired chromosome changes in the tumour,
but this is the first study to address this idea in breast
cancer. By comparing germline CNVs and tumour-specific
CNVs in matched breast tumour and normal tissue using
data from the Illumina Human CNV370 duo beadarray, we
provide evidence that germline CNVs do not tend to act as
a foundation on which larger chromosome copy number
aberrations develop in tumour cells. Further studies are
required with increased sequence resolution that will detect
smaller CNVs and define CNV breakpoints to compre-
hensively assess the relationship between inherited geno-
mic variation and genome evolution in breast cancer.
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Introduction
Familial and sporadic forms of breast cancer are now
recognised to be a complex and heterogeneous disease at
both the clinical and molecular levels [1–4]. The genome
of a breast tumour typically represents a culmination of
somatically acquired, poorly understood, genomic aberra-
tions that functionally alter genes contributing to tumo-
urigenesis [5]. The extent of genomic abberation in breast
cancer has been shown to differ significantly in histological
subtype, such as low- and high-grade tumours [6, 7]. Since
patients with high-grade tumours generally have worse
prognosis than those who have low-grade tumours [8],
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these findings indicate that there is an association between
the mutational burden of tumours and tumour pathogenesis.
Similarly, basal-like breast tumours are characterised by
high levels of genomic aberrations in comparison to other
tumour subtypes, such as the luminal A or luminal B
subtypes [1], and are associated with poor prognosis [9]. A
number of phenotypical and molecular features are shared
by basal-like breast cancer and tumours arising in BRCA1
germline mutation carriers, including high grade and a high
number of chromosome copy number changes [10]. This
suggests a common tumourigenic pathway of the BRCA1
and basal-like subtypes; however, the biological mecha-
nisms associated with increased frequency of chromosomal
changes in these tumour types are currently poorly under-
stood.
Studies of choroid plexus tumours in Li–Fraumeni
Syndrome (LFS)-affected families [11] and of colon can-
cer-affected individuals [12] have suggested that constitu-
tional copy number variants (CNVs) may act as a
foundation on which chromosome copy number aberrations
develop in tumour cells. These findings suggest a direct
relationship between constitutional genomic variation and
tumour genome evolution. However, the number of cancer
cases, where matched normal tissue was also assessed, was
relatively small for each of the choroid plexus tumour and
colon cancer studies (n = 4 and 5, respectively) [11, 12].
Furthermore, it is currently unknown whether germline
CNVs play a role in genomic instability associated with
breast tumour grade and breast tumour subtype. To address
this issue, we utilised single nucleotide polymorphism
array data from a previously published study [1] to com-
pare germline CNV and breast tumour-specific CNVs using
28 matched normal and tumour tissue pairs. Furthermore,
we reassessed the association between pathological fea-
tures, such as breast tumour subtype and histological grade,




Twenty-eight breast cancer affected women participating
in this study were from multi-case families who had been
recruited into the Kathleen Cuningham Foundation for
Research into Breast Cancer (kConFab) [13]. Of these, 9
carried a mutation in BRCA1, 7 carried a mutation in
BRCA2 and 12 were mutation negative (BRCAx) after full
sequencing and multiplex ligation-dependant probe
amplification (MLPA) analysis of BRCA1/2. The histo-
logical features of all tumours were reviewed by a
pathologist who also scored the percentage of neoplasia in
the specimen prior to DNA isolation, as previously
described [1]. The molecular subtype (luminal A, luminal
B, HER2, basal and normal breast-like) for each tumour
had been earlier determined by Waddell et al. [1].
Genome-wide SNP genotyping
SNP genotyping data were generated from 28 matched
tumour and normal tissue using Illumina arrays containing
370,000 SNPs. Tissue samples of the primary tumour and
matching normal tissue were obtained by macrodissec-
tioning frozen sections of 10 lm with a needle, ensuring
that the neoplastic content was[75%. DNA was extracted
by the salting-out method followed by a phenol chloroform
extraction. The Infinium II assay protocol (Illumina Inc.,
San Diego, CA) was used to perform whole genome
amplification. DNA of 750 ng was fragmented and hybri-
dised to Illumina Human CNV370 duo beadarrays [1].
CNV calling and data analysis
Germline and tumour-specific CNVs were determined
using the SNP array data for all 28 matching tissue pairs.
Data were imported and visualised in GenomeStudio
Software v2010.3, and the B-allele frequencies and logR
ratios were exported for each sample. The software pack-
age R was used to perform SOMATICS [14] to identify
regions containing CNVs, as previously described [1].
SOMATICS was used as it can analyse SNP data from
tissues which are heterogeneous due to the presence of
stromal contamination or multiple tumour clones. For
technical validation of predicted CNVs, comparative qPCR
was performed as described previously [1]. Galaxy genome
analysis tools [15] were utilised for mapping CNVs to the
hg18 build of the human genome and to perform inter-
section and subtraction, to compute base coverage and to
obtain flanking sequences.
In this study, we defined tumour-specific CNV regions
as those which show copy number change in the tumour
genome but do not overlap germline CNV regions identi-
fied in the genome of the matched normal tissue. To
account for the possibility that contiguous CNVs called by
SOMATICS may represent a single larger CNV, especially
in the tumour genome, we have measured the base pair
coverage of these variants as opposed to their frequency.
Our hypothesis that germline CNVs are ‘hotspots’ for
tumour-specific CNVs, and hence that the fraction of
tumour-specific CNVs located in proximity to germline
CNVs is higher than expected was tested in silico. First, we
estimated the expected fraction of genomic DNA contain-
ing tumour-specific CNVs in proximity to germline CNVs.
For each sample, mock CNVs of the same size as the
observed set of tumour-specific CNVs were randomly
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distributed over the human genome. Using these data, we
computed the fraction of randomly placed CNVs in prox-
imity to a germline CNV (overlapping or less than 1,000 bp
downstream or upstream). This simulation was repeated
2,000 times for each sample. The average fraction of ran-
domly placed CNVs in proximity to a germline CNV was
used as the expected fraction. Second, we tested the
hypothesis ‘the fraction of tumour-specific CNVs located
in proximity to a germline CNV is higher than expected’
with the paired-Wilcoxon rank test (P \ 0.05). Genomic
coordinates corresponding to germline CNVs and tumour-
specific CNVs used in this analysis are listed in Table S1
(Supplementary material). A schematic representation of
the experimental design is illustrated in Fig. S1 (Supple-
mentary material).
Results
DNA copy number profiles of matched breast tumour
and normal tissue pairs
The germline DNA copy number profiles of our study
cohort show that on average, 2.6% (range 0.6–7.0%) of a
haploid genome was affected by copy number change
(Table S2, Supplementary material). By comparison,
analysis of DNA from matched breast tumour tissue
revealed copy number changes that covered 37.6% (range
10.5–70.1%) of the haploid genome (Table S2, Supple-
mentary material) and tumour-specific copy number
(germline CNV regions excluded) changes covering 36.4%
(range 10.0–69.3%) of the haploid genome. These results
therefore show that germline CNVs covering an average of
1.4% of the genome are not detected in the tumour genome.
There are several potential explanations for this difference,
including the possibility that (1) the genomic regions
containing germline CNVs may change copy number status
after further rearrangement of the tumour; (2) the com-
plexity of the structural rearrangements in the tumour
genome results in a failure to call some tumour CNVs by
SOMATICS and (3) a proportion of CNVs in the germline
DNA are miscalled.
No significant difference was observed in the number of
base pairs affected by germline CNVs when comparing
cases by mutation status, histological grade of the tumour
and basal/non-basal subtype (Table 1). However, a com-
parison of germline CNV base pair coverage between cases
with luminal A and luminal B tumours did show a twofold
increase in coverage for luminal A cases that was moder-
ately significant (P = 0.04; Table 1).
In contrast to germline CNVs, and as previously dem-
onstrated [1], the average number of base pairs affected by
copy number change within the tumours differed signifi-
cantly between molecular subtypes and to a lesser degree, by
mutation status (Fig. 1a, b; Table 1). This difference was
most striking (twofold, P = 10-7) when comparing geno-
mic profiles from basal and non-basal breast tumours
(Fig. 1b; Table 1). The average number of base pairs
affected by copy number change also differed significantly
(twofold, P = 0.007) when classified by histological grade
(Fig. 1c; Table 1). This finding is concordant with previous
studies that have reported the frequency of genomic aber-
rations in grade III breast tumours to be greater than those
found in grade I or II tumours [7, 16–18]. Sample numbers
limited the number of statistical comparisons that could be
carried out between the various molecular subtypes.
Table 1 Genomic coverage of germline and tumour-specific CNV regions
n Germline CNV regions Tumour-specific CNV regions
Average base pair coverage Pa Average base pair coverage Pa
Mutation status
BRCA1 9 79,801,545 0.70(BRCA1 vs BRCA2) 1,359,740,736 0.03(BRCA1 vs BRCA2)
BRCA2 7 70,879,436 0.52(BRCA2 vs BRCAx) 890,264,516 0.39(BRCA2 vs BRCAx)
BRCAx 12 84,758,924 0.84(BRCA1 vs BRCAx) 1,092,785,789 0.23(BRCA1 vs BRCAx)
Molecular subtype
Basal 13 68,410,342 0.27(Basal vs all other subtypes) 1,560,362,706 10
-7
(Basal vs all other subtypes)
Her2 2 73,290,002 1,141,773,431
Luminal A 8 114,241,923 550,866,350
Luminal B 4 57,603,536 0.04(LumA vs LumB) 1,074,264,196 10
-4
(LumA vs LumB)
Normal 1 51,213,066 310,698,090
Histological grade
Grade II 6 111,118,574 658,829,402
Grade III 21 73,035,723 0.20(Grade II vs Grade III) 1,245,855,304 0.007(Grade II vs Grade III)
a Two-tailed Student’s t test
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Fig. 1 Base pair coverage of germline and tumour-specific CNV regions as stratified by a patient mutation status, b breast tumour subtype and
c breast tumour grade
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However, we were able to compare the genomic profiles of
luminal A and luminal B tumours, and found that the CNV
coverage in luminal B tumours was twofold greater than that
in luminal A tumours (P \ 10-4; Table 1). This difference
is not explained by the observation that four of the eight
luminal A tumours were also grade II, as a comparison of
luminal A and luminal B grade III tumours also showed a
significant difference in base pair coverage (P = 0.0002).
Correlating the location of germline CNVs
with tumour-specific CNVs in paired tumour tissue
To assess whether germline CNVs act as ‘hotspots’ for
tumour-specific CNVs, we tested the hypothesis that
tumour-specific CNVs are preferentially located in prox-
imity to germline CNVs. On average, 18.8% (range
1.8–38.7%) of haploid genomes from the breast tumours
evaluated in this study consisted of tumour-specific CNVs
that either overlapped or were located within 1 kb of a
germline CNV. This equates to approximately half of the
total number of base pairs that are affected by tumour-
specific CNVs (36.4%, range 10.0–69.3%). To determine
whether these germline CNVs are hotspots for tumour-
specific CNVs, we simulated events using observed CNV
sizes and calculated the fraction of randomly placed
tumour-specific CNVs in proximity to a germline CNV. We
found that the overall difference between actual and simu-
lated events was not significant (P = 0.97; Fig. 2; Table 2).
Only 10 of 28 cases showed greater proximity between the
actual germline CNVs and tumour-specific CNVs and
represented all tumour subtypes (Table 2). By comparison,
the proximity between randomised intervals of germline
CNVs and tumour-specific CNVs in 18 of the 28 cases was
slightly greater than that between actual intervals of
germline CNVs and tumour-specific CNVs (Table 2). This
was also the case for 9 of the 13 basal-like tumours sug-
gesting that germline CNVs in these tumours are not located
in genomic regions that give rise to somatically acquired
changes. Together these findings suggest that the location of
tumour-specific CNVs is not biased by germline CNVs.
Discussion
Similar to sporadic breast tumours, familial breast tumours
can be classified into at least five molecular subtypes that are
clinically distinct [1]. Of these subtypes, the basal-like
tumour subtype, which is common in BRCA1 mutation
carriers, is characterised by a high number of chromosomal
copy number changes. Genomic instability is also a
molecular feature of tumours with high-histological grade
that, analogous to basal-like tumours, are typically aggres-
sive lesions. The ability to predict which breast cancer
patients will develop tumours with extensive genomic
instability will undoubtedly be a valuable tool in clinical
diagnostics. To our knowledge, this is the first study to test
the hypothesis that variation in genotype as a result of
inherited copy number changes contributes to genomic
instability within breast tumour cells. In contrast to the
previous small studies [11, 12] that evaluated choroid plexus
and colon carcinomas, our results using 28 matched breast
tumour and normal tissue suggest that, at a whole genome
level, there is no evidence of an association between the
genomic location of germline CNVs and breast tumour-
specific CNVs using matched normal and tumour pairs.
Consistent with a previous study of familial breast
tumours, we found that CNV base pair coverage in luminal
B tumours was significantly greater than that in luminal A
tumours [19]. However, we show that this difference was
independent of breast tumour grade. Compared to luminal
A tumours, luminal B tumours are known to have higher
cellular proliferation and confer poorer prognosis [20]. Our
results suggest that the chromosomal instability phenotype,
but not the differentiated state of the tumour cells, con-
tributes to the aggressive nature of luminal B tumours.
A previous study found a significant association
between known CNV loci and de novo chromosome breaks
in colon cancer [12], suggesting that germline CNVs and
tumour-specific CNVs are likely to be located at chromo-
some regions that are most prone to breakage. However, it
remains to be determined whether sequences at these loci
predispose to further genomic instability after copy number
change has occurred in the germline DNA. Our study went
some way to investigate this issue; however, there are
Fig. 2 Proximity of tumour-specific CNVs to germline CNVs from
actual and simulated data. Each dot represents for one patient the
fraction of observed and expected (randomly placed) tumour CNVs in
proximity to a germline CNV
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notable limitations with the current dataset. First, the exact
boundaries of predicted CNVs cannot be precisely deter-
mined using microarray-based platforms, and it is therefore
impossible to characterise the breakpoint sequences that
are involved in the copy number change without further
sequence analysis. Second, it is unclear as to the precise
location of duplicated or amplified CNVs in that some
CNV units may not be located in tandem but may map to
different chromosomes entirely; confounding studies
assessing their contribution to somatically acquired geno-
mic events. Whole genome high-resolution technologies,
such as next-generation sequencing, will be required to
accurately map the location of each CNV amplicon to
better ascertain which sequences contribute to tumour
genome instability. Third, SOMATICS was not able to
discriminate heterozygous loss and gain for some predicted
CNVs. Thus, we were only able to identify copy number
variable regions that had undergone copy number change
but were unable to classify many of these regions by exact
copy number status. Forth, germline DNA used by Waddell
et al. [1] was obtained from breast tissue that appears
histologically normal but may potentially harbour somati-
cally acquired copy number changes. Although DNA from
peripheral blood cells or buccal cells would have prevented
such possibility, recent evidence suggests that the detection
of clonal changes in normal tissue found adjacent breast
tumours would be unlikely [21, 22].
The notion that inherited CNVs may influence incidence
of the various genomic copy number changes that occur
during breast cancer progression has not only prognostic
significance, but also important consequences for early
decisions relating to clinical management. Although our
findings suggest no association globally across the genome, it
is still possible that some germline CNVs may indeed mark
regions that are prone to further rearrangement in the breast
tumour. Further work is therefore required using the latest
Table 2 Proximity of tumour-specific CNVs to germline CNVs from actual and simulated data (2000 replications per sample)
Sample ID Mutation status Original bp fraction
in proximity (x)
Simulated bp fraction in proximity Difference (x - y)
Average fraction (y) Minimum fraction Maximum fraction
B7 BRCA1 0.78 0.82 0.69 0.90 -0.03
B8 BRCA1 0.65 0.71 0.44 0.84 -0.07
B9 BRCA1 0.12 0.22 0.10 0.38 -0.10
B11 BRCA1 0.47 0.37 0.20 0.53 0.11
B15 BRCA1 0.43 0.52 0.35 0.68 -0.09
B16 BRCA1 0.67 0.67 0.43 0.82 0.00
B19 BRCA1 0.51 0.44 0.23 0.64 0.06
B21 BRCA1 0.25 0.36 0.16 0.54 -0.11
B22 BRCA1 0.50 0.48 0.30 0.64 0.03
B2 BRCA2 0.47 0.54 0.37 0.74 -0.06
B3 BRCA2 0.26 0.34 0.08 0.54 -0.08
B5 BRCA2 0.50 0.50 0.27 0.67 -0.01
B12 BRCA2 0.22 0.25 0.04 0.44 -0.02
B13 BRCA2 0.42 0.50 0.27 0.69 -0.08
B17 BRCA2 0.21 0.38 0.00 0.71 -0.16
B27 BRCA2 0.84 0.78 0.62 0.86 0.06
B1 BRCAx 0.87 0.87 0.70 0.92 0.00
B4 BRCAx 0.24 0.29 0.13 0.45 -0.04
B6 BRCAx 0.74 0.75 0.54 0.84 -0.01
B10 BRCAx 0.61 0.66 0.52 0.77 -0.05
B14 BRCAx 0.26 0.32 0.10 0.54 -0.06
B18 BRCAx 0.56 0.55 0.30 0.74 0.01
B20 BRCAx 0.67 0.67 0.50 0.79 0.00
B23 BRCAx 0.55 0.47 0.03 0.70 0.08
B24 BRCAx 0.85 0.78 0.62 0.87 0.08
B25 BRCAx 0.45 0.47 0.28 0.64 -0.02
B26 BRCAx 0.26 0.29 0.08 0.49 -0.03
B28 BRCAx 0.26 0.32 0.00 0.54 -0.06
bp Base pair
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genomic sequencing technologies to precisely map CNV
breakpoints sequences across the genome to determine the
relationship between inherited genomic variation and gen-
ome evolution in breast cancer. Moreover, studies with larger
cohort size are warranted to assess our finding in familial
breast tumours, that the genome of high-grade luminal A
tumours had significantly less CNV coverage than the more
clinically aggressive high-grade luminal B tumours.
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